Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Holding VRTX?
Track your performance easily
Earnings Data
Report Date
Feb 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
3.99Last Year’s EPS
4.2Same Quarter Last Year
Moderate Buy
Based on 26 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 24, 2018
|% Change Since: -11.81%
|Next Earnings Date:Jul 25, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance and positive momentum for Vertex, with notable revenue growth, successful product launches, and significant pipeline advancements. However, challenges remain in treatment center expansion, opioid crisis costs, and regulatory complexities in specific programs.Company Guidance
During the Vertex Pharmaceuticals Q3 2024 earnings call, the company provided robust financial and operational guidance, highlighting significant achievements and future plans. Vertex reported a 12% year-over-year increase in revenue, amounting to $2.77 billion for the third quarter, and raised its full-year product revenue guidance to between $10.8 billion and $10.9 billion. The company maintained its non-GAAP operating expense guidance of $4.2 billion to $4.3 billion. Vertex's commercial execution was strong, notably in cystic fibrosis (CF) markets, generating $2.77 billion in revenue this quarter alone, reflecting a 12% growth compared to Q3 2023. Vertex also discussed its pipeline advancements, including the progression of three new programs into Phase III trials and preparations for two potential product launches in early 2025. The company highlighted the early success of CASGEVY's launch, with 45 authorized treatment centers and approximately 40 patients having undergone cell collection, as well as the strategic initiatives underway to support the anticipated launch of suzetrigine for moderate-to-severe acute pain.Strong Revenue Growth in Cystic Fibrosis
Vertex delivered $2.77 billion in revenue, representing a 12% growth this quarter versus Q3 2023. Full year product revenue guidance increased to $10.8 billion to $10.9 billion.
Commercial Launch Success of CASGEVY
Early launch of CASGEVY is going well with high enthusiasm from patients and physicians. The first patient received commercial CASGEVY, marking the first revenue recognition for this medicine.
Pipeline Advancements and New Phase III Trials
Three new programs advanced into Phase III clinical trials last quarter, including VX-880 in Type 1 diabetes and povetacicept in IgA nephropathy.
Regulatory Progress and Approvals
CASGEVY received approvals in Switzerland and Canada, and the first commercial patients received their infusions. Regulatory discussions are underway in the Middle East.
Financial Performance and Share Repurchase
Vertex reported non-GAAP operating income of $1.31 billion and repurchased over 1.7 million shares year-to-date, deploying over $750 million.
---
VRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $472.80 | $499.88 | +5.73% |
| Aug 01, 2024 | $505.78 | $494.46 | -2.24% |
| May 06, 2024 | $402.50 | $410.24 | +1.92% |
| Feb 05, 2024 | $428.89 | $416.13 | -2.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vertex Pharmaceuticals (VRTX) report earnings?
Vertex Pharmaceuticals (VRTX) is schdueled to report earning on Feb 11, 2025, TBA Not Confirmed.
What is Vertex Pharmaceuticals (VRTX) earnings time?
Vertex Pharmaceuticals (VRTX) earnings time is at Feb 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRTX EPS forecast?
VRTX EPS forecast for the fiscal quarter 2024 (Q4) is 3.99.
---